NaV1.7 Inhibitor

About Channel Therapeutics

Channel Therapeutics is a preclinical biotech targeting the urgent need for non-opioid pain management. The company's core asset is a patented, potent, and selective inhibitor of the human NaV1.7 sodium channel, which has shown efficacy in multiple preclinical pain models. Its strategy is to pursue orphan drug designations for rare pain conditions like Erythromelalgia and Idiopathic Small Fiber Neuropathy to accelerate development, while also exploring broader applications in eye pain and other indications. The company is private and pre-revenue, seeking investment to advance its lead compound toward clinical trials.

About Channel Therapeutics

Channel Therapeutics is a preclinical biotech targeting the urgent need for non-opioid pain management. The company's core asset is a patented, potent, and selective inhibitor of the human NaV1.7 sodium channel, which has shown efficacy in multiple preclinical pain models. Its strategy is to pursue orphan drug designations for rare pain conditions like Erythromelalgia and Idiopathic Small Fiber Neuropathy to accelerate development, while also exploring broader applications in eye pain and other indications. The company is private and pre-revenue, seeking investment to advance its lead compound toward clinical trials.

Therapeutic Areas